370 related articles for article (PubMed ID: 30003113)
41. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
42. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
44. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
[TBL] [Abstract][Full Text] [Related]
46. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Liu T; Greenberg M; Wentland C; Sepe B; Bowe S; Diercks G; Huynh T; Mino-Kenudson M; Schlegel R; Kodack D; Benes C; Engelman J; Hartnick C
Int J Pediatr Otorhinolaryngol; 2017 Apr; 95():133-138. PubMed ID: 28576522
[TBL] [Abstract][Full Text] [Related]
48. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
[TBL] [Abstract][Full Text] [Related]
49. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
50. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
51. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
52. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
53. Fatty Acid Oxidation Controls CD8
Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
[TBL] [Abstract][Full Text] [Related]
54. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
55. Classification of gallbladder cancer by assessment of CD8
Lin J; Long J; Wan X; Chen J; Bai Y; Wang A; Yang X; Wu Y; Robson SC; Sang X; Zhao H
BMC Cancer; 2018 Jul; 18(1):766. PubMed ID: 30055582
[TBL] [Abstract][Full Text] [Related]
56. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
57. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
58. Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
Guo L; Liu Z; Zhang Y; Quan Q; Huang L; Xu Y; Cao L; Zhang X
Medicine (Baltimore); 2019 Feb; 98(8):e14663. PubMed ID: 30813210
[TBL] [Abstract][Full Text] [Related]
59. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
60. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
